Table 4. Comparison between GS 6 disease and more aggressive disease in PCa patients.
| Variables | GS 6 | GS ≥ 7 | P value |
|---|---|---|---|
| No. of patients | 40 | 85 | - |
| Age, yr | 69.3 (9.2) | 72.9 (7.9) | 0.047 |
| Prostate volume, mL | 34 (13–102) | 33 (15–209) | 0.981 |
| tPSA, ng/mL | 5.8 (3.6–52.8) | 14.3 (3.9–387.2) | < 0.001 |
| %fPSA | 0.14 (0.01–13.09) | 0.12 (0.03–0.47) | 0.018 |
| p2PSA, pg/mL | 14.1 (0.7–141.1) | 37.6 (7.1–349.6) | < 0.001 |
| %p2PSA | 1.2 (0.1–3.8) | 2.2 (0.6–11.9) | < 0.001 |
| PHI | 33.6 (1.7–77.8) | 85.6 (35.6–721.3) | < 0.001 |
Data are shown as mean (SD), median (range), or number (%).
SD = standard deviation, PSA = prostate-specific antigen, tPSA = total PSA, fPSA = free PSA, p2PSA = [-2]proPSA, PHI = prostate health index, GS = Gleason score, PCa = prostate cancer.